Report of Foreign Issuer (6-k)
24 November 2016 - 1:32AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of
|
|
November
|
|
2016
|
Commission File Number
|
|
001-36458
|
|
|
Neovasc Inc.
|
(Translation of registrant’s name into English)
|
Suite 5138
– 13562 Maycrest Way
Richmond,
British Columbia, Canada V6V 2J7
|
(Address of principal executive offices)
|
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
DOCUMENTS INCLUDED AS PART OF THIS REPORT
Document
|
|
|
|
|
|
1
|
|
News
Release dated November 23, 2016 - Neovasc Announces Dismissal of Class Action Lawsuit
|
Document 1
Neovasc Announces Dismissal of Class Action Lawsuit
NASDAQ: NVCN
TSX: NVC
VANCOUVER, Nov. 23, 2016 /CNW/ - Neovasc Inc. ("
Neovasc
"
or the "
Company
") (NASDAQ: NVCN) (TSX: NVC) announced today that the United States District Court for the District
of Massachusetts granted the Company's motion to dismiss with prejudice in the case of Grobler v. Neovasc Inc, et al., Civil Action
No. 16-11038-RGS, a putative securities class action that was filed on June 6, 2016 against the Company and certain of the Company's
officers.
The Court ruled in favor of the Company and its officers on
all claims and ordered the entire case closed. The Company is not aware as to whether, and presently cannot foresee whether,
the plaintiff will appeal the dismissal of his claims or will file any post-dismissal motions.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular
marketplace. Its products in development include the Tiara™, for the transcatheter treatment of mitral valve disease
and the Neovasc Reducer™ for the treatment of refractory angina. The Company also sells a line of advanced biological tissue
products that are used as key components in third-party medical products including transcatheter heart valves. For more information,
visit: www.neovasc.com.
This news release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws, including statements
regarding any future developments in the class action litigation, including any potential appeals and post-dismissal motions. The
words "cannot foresee" and "will" are intended to identify these forward-looking statements. Forward-looking
statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical
trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate
in the circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements
to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, potential
changes in circumstances relating to litigation involving the Company, whether as a result of unforeseen circumstances or otherwise;
and the conduct or possible outcomes of any actual or threatened legal proceedings, including any post-dismissal motions or appeals,
which are inherently uncertain. Risk factors concerning the class action litigation and others relating to the Company were previously
discussed in greater detail in the "Risk Factors" section of the Company's Annual Information Form, which is included
in its Annual Report on Form 40-F (copies of which filings may be obtained at www.sedar.com or www.sec.gov).
These factors should be considered carefully, and readers should not place undue reliance on the Company's forward-looking statements.
The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required by law.
SOURCE Neovasc Inc.
%CIK: 0001399708
For further information:
Investor Relations: Neovasc Inc.,
Chris Clark, 604 248-4138, cclark@neovasc.com
CO: Neovasc Inc.
CNW 08:14e 23-NOV-16
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Neovasc Inc.
|
|
(Registrant)
|
|
|
Date:
November 23,
2016
|
By:
|
/s/
Chris Clark
|
|
Name:
|
Chris Clark
|
|
Title:
|
Chief Financial Officer
|
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neovasc (NASDAQ:NVCN)
Historical Stock Chart
From Jul 2023 to Jul 2024